A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 620-622

  Hori, Hikaru ^a   Yoshimura, Reiji ^a   Ueda, Nobuhisa ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Depression; Fluvoxamine; Paroxetine; Plasma concentration

Indexed keywords

FLUVOXAMINE; MILNACIPRAN; PAROXETINE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6;

ADULT; AGITATION; ANAMNESIS; ANXIETY; ARTICLE; CASE REPORT; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MOOD DISORDER; NAUSEA; ORTHOSTATIC HYPOTENSION; SOMNOLENCE; STEADY STATE; BLOOD; DRUG COMBINATION; DRUG INTERACTION; PSYCHOLOGICAL ASPECT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HUMANS; PAROXETINE;

EID: 77449106194     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970802118349     Document Type: Article

References (22)

1. Asberg M, Cronholm B, Sjoquvist F, Tuck D. 1971. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 3:331-334.
2. Benfield P, Ward A. 1986. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drug 13:313-334. (Pubitemid 16028714)
3. Brosen K. 1998. Differences in interactions of SSRIs. Int Clin Psychopharmacol 13(Suppl 5):45-47.
4. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft. 1993. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 45:1211-1214.
5. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. 1996. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2. Clin Pharmacol Ther 60:183-190.
6. De Wilde JEM, Doogan DP. 1982. Fluvoxamine and clomipramine in endogeneous depression. J Affect Disord 4:249-259.
7. Gerstenberg G, Aoshima T, Fukusawa T, Yoshida K, Takahashi H, Higuchi H, et al. 2003. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentarations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology 167: 443-448. (Pubitemid 36754247)
8. Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. 1977. Clinical implication of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 34:197-204.
9. Ikenouchi-Sugita A, Yoshimura R, Hori H, Ueda N, Nakamura J. 2007. Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa. Psychiatry Clin Neurosci 61:452.
10. Kasper S, Dotsch M, Kick H, Viera A, Moller HJ. 1993. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 3:13-21.
11. Mihara K, Yasui-Furukori N, Kondo T, Ishida M, Ono S, Ohkubo T, et al. 2002. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit 24:563-566.
12. Nelson JC, Jatlow P, Quinlan DM, Bowers MB. 1982. Desipra-mine plasma concentration and antidepressant response. Arch Gen Psychiatry 39:1419-1422.
13. Otani K, Kaneko S, Sasa H, Kondo T, Fukushima Y 1991. Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin? Hum Psychopharmacol 6:243-248.
14. Palmer KJ, Benfield P. 1994. Fluvoxamine: an overview of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. CNS Drugs 1:57-87.
15. Papakostas GI, Charles D, Fava M. 2007. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 13:1-8.
16. Perucca KJ, Gatti G, Spina E. 1994. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 27:175-190.
17. Ruhe HG, Huyser J, Swinkels JA, Schene AH. 2006. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67:1836-1855. (Pubitemid 46055194)
18. Sandson NB. 2003. Drug Interactions Case Book. Washington, DC: American Psychiatric Publishing.
19. Ueda N, Yoshimura R, Shinkai K, Terao T, Nakamura J. 2001. Characteristics of fluvoxamine-induced nausea. Psychiatry Res 104:259-264.
20. Ueda N, Yoshimura R, Nakamura J. 2008. Fluvoxamine improves some depressive symptoms by influencing noradrenergic neurons. Psychiatry Res (in press)
21. Vandel P. 2003. Antidepressant drugs in the elderly-role of the cytochrome P450 2D6. World J Biol Psychaitry 4:74-80.
22. Von Moltke LL, Greenblatt DJ, Court MH. 1995. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131.